0001437749-15-005080.txt : 20150313 0001437749-15-005080.hdr.sgml : 20150313 20150313192208 ACCESSION NUMBER: 0001437749-15-005080 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150312 FILED AS OF DATE: 20150313 DATE AS OF CHANGE: 20150313 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HYPERION THERAPEUTICS INC CENTRAL INDEX KEY: 0001386858 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 611512713 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2000 SIERRA POINT PARKWAY STREET 2: SUITE 400 CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 650-745-7802 MAIL ADDRESS: STREET 1: 2000 SIERRA POINT PARKWAY STREET 2: SUITE 400 CITY: BRISBANE STATE: CA ZIP: 94005 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nash Christine A CENTRAL INDEX KEY: 0001554403 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35614 FILM NUMBER: 15700768 MAIL ADDRESS: STREET 1: C/O HYPERION THERAPEUTICS, INC. STREET 2: 2000 SIERRA POINT PARKWAY, SUITE 400 CITY: BRISBANE STATE: CA ZIP: 94005 4 1 rdgdoc.xml FORM 4 X0306 4 2015-03-12 0001386858 HYPERION THERAPEUTICS INC HPTX 0001554403 Nash Christine A C/O HYPERION THERAPEUTICS, INC. 2000 SIERRA POINT PARKWAY, SUITE 400 BRISBANE CA 94005 1 SVP & Chief Commercial Officer Common Stock 2015-03-10 4 M 0 10000 4.08 A 29003 D Common Stock 2015-03-10 4 S 0 10000 35.08 D 19003 D Stock Option (Right to Buy) 4.08 2015-03-12 4 M 0 10000 0 D 2021-04-14 Common Stock 32709 22709 D The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 15, 2014. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions ranging in price from $35.00-35.36. The reporting person undertakes to provide Hyperion Therapeutics, any security holder of Hyperion Therapeutics or the staff of the Securities and Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in footnote (2) to this Form 4. The shares acquired upon exercise of portion of option exercised were fully vested and exercisable. The option began vesting on April 15, 2011, at a rate of 1/48th per month. /s/ Sally Brammell, Attorney-in-fact 2015-03-13